{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:53:05Z","timestamp":1769554385054,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.diabres.2022.109973","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T12:08:28Z","timestamp":1656245308000},"page":"109973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis"],"prefix":"10.1016","volume":"190","author":[{"given":"Norio","family":"Abiru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Kosakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Snijder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Rokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10138","key":"10.1016\/j.diabres.2022.109973_b0005","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2022.109973_b0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.metabol.2013.10.002","article-title":"Type 1 diabetes, metabolic syndrome and cardiovascular risk","volume":"63","author":"Chillar\u00f3n","year":"2014","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.diabres.2022.109973_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13340-015-0248-5","article-title":"A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes-JDCP study 2","volume":"7","author":"Nishimura","year":"2016","journal-title":"Diabetol Int"},{"issue":"10","key":"10.1016\/j.diabres.2022.109973_b0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2213-8587(20)30311-9","article-title":"SGLT2 inhibitors and renal complications in type 1 diabetes","volume":"8","author":"Petrie","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2022.109973_b0025","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2022.109973_b0030","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 Diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2022.109973_b0035","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/dom.13807","article-title":"Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial","volume":"21","author":"Kaku","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2022.109973_b0040","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as Adjunctive to inSulin thErapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2022.109973_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3169","article-title":"Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"35","author":"Lu","year":"2019","journal-title":"Diabetes\/Metab Res Rev"},{"key":"10.1016\/j.diabres.2022.109973_b0050","unstructured":"Japanese Medical Database Center. JMDC Claims Database. Available from: https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/ [accessed December 6, 2021]."},{"key":"10.1016\/j.diabres.2022.109973_b0055","unstructured":"Nakashima N, Yamashita T, Izukura R, Nojiri C, Tokunaga S, Nishikitani M. Research on the actual condition of type 1 diabetes mellitus, objective diagnostic criteria, and the development of a severity assessment focusing on daily life and social life: a study for the extraction of type 1 diabetes mellitus cases and the construction of a type 1 diabetes mellitus registration database (Assignment 8) [Japanese]. Available from: https:\/\/mhlw-grants.niph.go.jp\/system\/files\/2017\/172031\/201709008A_upload\/201709008A0012.pdf [accessed March 22, 2022]."},{"issue":"5","key":"10.1016\/j.diabres.2022.109973_b0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"11","key":"10.1016\/j.diabres.2022.109973_b0065","first-page":"721","article-title":"Validating the adapted Diabetes Complications Severity Index in claims data","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.diabres.2022.109973_b0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.diabres.2022.109973_b0075","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/jdi.13506","article-title":"On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes","volume":"12","author":"Horii","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"5","key":"10.1016\/j.diabres.2022.109973_b0080","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/jdi.13240","article-title":"Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: a retrospective, single-center, pilot study","volume":"11","author":"Suzuki","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"12","key":"10.1016\/j.diabres.2022.109973_b0085","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1507\/endocrj.EJ21-0161","article-title":"Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study","volume":"68","author":"Shimoda","year":"2021","journal-title":"Endocr J"},{"issue":"4","key":"10.1016\/j.diabres.2022.109973_b0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14656566.2016.1145668","article-title":"Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): interim results of a post-marketing surveillance study","volume":"17","author":"Terauchi","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabres.2022.109973_b0095","doi-asserted-by":"crossref","unstructured":"The Committee on the Proper Use of SGLT2 Inhibitors. Recommendations on the Proper Use of SGLT2 Inhibitors. J Diabetes Invest 2020;11(1):257\u201361. https:\/\/doi.org\/10.1111\/jdi.13160.","DOI":"10.1111\/jdi.13160"},{"issue":"6","key":"10.1016\/j.diabres.2022.109973_b0100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1507\/endocrj.K08E-167","article-title":"Association between body mass index and core components of metabolic syndrome in 1486 patients with type 1 diabetes mellitus in Japan (JDDM 13)","volume":"55","author":"Arai","year":"2008","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.diabres.2022.109973_b0105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/jdi.13547","article-title":"Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index","volume":"13","author":"Mitsui","year":"2022","journal-title":"J Diabetes Invest"},{"issue":"6","key":"10.1016\/j.diabres.2022.109973_b0110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2022.109973_b0115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1507\/endocrj.EJ17-0491","article-title":"Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials","volume":"65","author":"Kashiwagi","year":"2018","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.diabres.2022.109973_b0120","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.diabres.2022.109973_b0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabres.2006.01.013","article-title":"The status of diabetes control and antidiabetic drug therapy in Japan \u2013 a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1)","volume":"73","author":"Kobayashi","year":"2006","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722007872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722007872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:21:59Z","timestamp":1759173719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722007872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"alternative-id":["S0168822722007872"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109973","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109973"}}